Thanks for posting this, I am in wk 35, my HGB that had been holding steady in the 11's all though tx dropped to 8.9 and I was reduced from 1000 to 400 mg of riba and put back on weekly labs, I thought the reduction to 400 mg was a little drastic but I am in a trial and protocol states that if I drop below 8 it is a safety issue and I will be removed from the trial.
A very common question by very many people. Always good to reiterate and give documentation so people who are trying know that it is not just another "theory" but is based on clinical data.
While we assume this is also true for those treating with Boceprevir (as it is also a protease inhibitor) it would be nice if someone performed a retrospective sub-analyses of the SPRINT-2 (treatment naive) and RESPOND-2 (treatment experienced) studies also just so we have the data.
Thanks for posting!
I was also reduced to 400 mg of ribavirin when my hemoglobin dropped to 7.7.
Yes this is true, but only once one is Und. Trials showing a lower dose of riba starting out did not work out to well.
Heres a link, while this is on boceprevir the same applys to telaprevir.
As you can see below, lower dose = lower SVR rates... Once one becomes und they don't think it plays much of a factor in SVR rates.
Finally, in the SPRINT-1 study of boceprevir for genotype 1, treatment-naive patients, those receiving low-dose RBV achieved an SVR rate of only 36% vs 50% with standard weight-based RBV dosing, each combined with boceprevir and pegIFN
Its under Ribavirin
Well I see Incevik is getting on the band wagon too - like Victrelis.
However, there is still not enough information specifically on relapsers and cirrhotics. I hope the information posted in new studies is correct, but until they sort out the "hard to treat" I find the information significant only to treatment naive who (as can do said) have already achieved a UND.